Home/Healthcare/Rare Diseases/Global Neurodegenerative Diseases Market

Global Neurodegenerative Diseases Market - Strategic Insights and Forecasts (2026-2035)

Market Size, Share, Forecasts and Trends Analysis By Therapy Type (Pharmaceuticals, Biologics, Gene Therapies, Cell Therapies, Neurostimulation Devices, Digital Therapeutics), By Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Dopaminergic Agents, Monoclonal Antibodies, Antidepressants and Antipsychotics, Neuroprotective Agents, Immunomodulators), By Indication (Alzheimer’s Disease, Parkinson’s Disease, ALS, Huntington’s Disease, Lewy Body Dementia, Frontotemporal Dementia, Multiple System Atrophy, Spinocerebellar Ataxia), and Geography

$3,950
Single User License
Access Full Insights
Report OverviewSegmentationTable of ContentsCustomize Report

Request Customization

Tell us your specific requirements and we will customize this report for you.

📞

Your data is secure. We do not share information with any third party.

Global Neurodegenerative Diseases Market Report

Report IDKSI-008727
PublishedJun 2026
Pages158
FormatPDF, Excel, PPT, Dashboard

Need Assistance?

Our research team is available to answer your questions.

Contact Us
Frequently Asked Questions

The Global Neurodegenerative Diseases Market is projected to grow at a CAGR of 6.8%, increasing from USD 63.1 billion in 2026 to USD 114.2 billion by 2035, driven by rising disease prevalence and advancements in neurological therapies.

The Global Neurodegenerative Diseases Market is driven by aging populations, increasing Alzheimer’s and Parkinson’s prevalence, expansion of biomarker diagnostics, and growing adoption of disease-modifying therapies.

The Global Neurodegenerative Diseases Market includes pharmaceutical therapies, biologics, gene therapies, and neurostimulation devices used for symptom management and disease modification.

North America leads the Global Neurodegenerative Diseases Market due to advanced healthcare infrastructure, high adoption of innovative therapies, and strong neurological research investment.

The Global Neurodegenerative Diseases Market faces challenges such as high clinical trial failure rates, limited neurologist availability, and reimbursement constraints for advanced therapies.

Need data specifically for your business?Request Custom Research →
Related Reports

Trusted by the world's leading organizations

Weber Shandwick
veolia
Tri
tls
TeamViewer
GE Healthcare
Intel
Proctor and Gamble
ABB
Elkem
Defense Logistics Agency
Amazon